Mustang Bio Presented P-I/II Clinical Trial of MB-106 for Waldenstrom's Macroglobulinemia at 11th International Workshop
Shots:
- The company reported the results from the WM cohort & P-I/II trial evaluating MB-106 in patients with B-NHLs & CLL at Fred Hutchinson Cancer Center. MB-106 dose levels will be tested in each arm in the P-I study using a 3+3 design & the therapy is being developed in collaboration with Mustang and Fred Hutch
- As of Sept 2022, the results showed ORR (96%), a CR rate of 75% in a wide range of hematologic malignancies, 100% ORR & 2 in CR with WM, and 12 experienced CR for ≥12mos. (10 ongoing); 4 with CR for ≥2yrs. & the longest patient with CR @33mos., 6 with PR improved to CR, and all remain in ongoing CR
- 3 patients responded to treatment who were prior treated with CD-19 CAR T cell therapy, had high efficacy and a favorable safety profile with no CRS or ICANS ≥ grade 3
Ref: GlobeNewswire | Image: Mustang Bio
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
